SARS-CoV-2疫苗接种后IgG抗体产生及至6个月的持久性:北爱尔兰观察性研究
该研究评估接种牛津-阿斯利康COVID-19疫苗后采用AbC-19™侧流装置检测的刺突蛋白IgG抗体反应,采集北爱尔兰111人从接种前至首剂后6个月共五个时间点的血浆样本。结果显示首剂后3周86.9%可检出抗体,第二剂前降至74.7%,第二剂后3周升至99%,首剂后6个月降至90.5%;既往感染者各时间点抗体水平均显著高于未感染者。
要点
- 首剂后3周86.9%可检出IgG抗体,第二剂前降至74.7%,第二剂后3周升至99%。
- 首剂后6个月抗体可检出率降至90.5%。
- 既往感染者各时间点抗体水平均显著高于未感染者。
核心结论
- 几乎所有接种两剂牛津-阿斯利康疫苗的个体均产生强抗刺突蛋白抗体反应,且大多在首剂接种后6个月后仍持续存在。
研究设计与样本
- 北爱尔兰观察性研究,采集n=111人的血浆样本,多数>50岁和/或临床易感人群,从接种前至首剂后6个月共五个时间点采样。
主要发现
- 20.3%参与者在接种前可检出IgG反应,提示既往COVID-19。
- 首剂后3周86.9%参与者可检出抗体,第二剂前降至74.7%,第二剂后3周升至99%。
- 首剂后6个月可检出率降至90.5%。
- 各时间点既往感染者抗体水平均显著高于未感染者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study evaluates spike protein IgG antibody response following Oxford-AstraZeneca COVID-19 vaccination using the AbC-19™ lateral flow device. METHODS: Plasma samples were collected from n = 111 individuals from Northern Ireland. The majority were >50 years old and/or clinically vulnerable. Samples were taken at five timepoints from pre-vaccination until 6-months post-first dose. RESULTS: 20.3% of participants had detectable IgG responses pre-vaccination, indicating prior COVID-19. Antibodies were detected in 86.9% of participants three weeks after the first vaccine dose, falling to 74.7% immediately prior to the second dose, and rising to 99% three weeks post-second vaccine. At 6-months post-first dose, this decreased to 90.5%. At all timepoints, previously infected participants had significantly higher antibody levels than those not previously infected. CONCLUSION: This study demonstrates that strong anti-spike protein antibody responses are evoked in almost all individuals that receive two doses of Oxford-AstraZeneca vaccine, and which largely persist beyond six months after first vaccination.
引用
- Robertson LJ, Price R, Moore JS, et al. IgG antibody production and persistence to 6 months following SARS-CoV-2 vaccination: A Northern Ireland observational study. Vaccine. 2022. PMID: 35346536. doi:10.1016/j.vaccine.2022.02.087
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。